3208.9000 14.50 (0.45%)
NSE Aug 06, 2025 15:31 PM
Volume: 127.4K
 

logo
Dr. Lal Pathlabs Ltd.
06 Aug 2020, 12:00AM
3208.90
0.45%
Geojit BNP Paribas
The company's growth in COVID business, strong brand recall, gradual unlock of cities should support growth in upcoming quarters. Given the limited upside potential we downgrade our rating to HOLD with a revised target price of Rs. 1,995 based on 53x FY22E EPS. COVID-19 tests contribute to the top line DLPL's Q1FY21 top line went down 20.6% YoY to Rs. 266cr severely impacted by COVID-19 and subsequent lock down impacting the revenue in April (-61% YoY) and May (-12% YoY), however some respite was seen in June (+14% YoY) when cities were...
Emkay released a Buy report for Dr. Lal Pathlabs Ltd. with a price target of 3100.0 on 20 Jul, 2025.
More from Dr. Lal Pathlabs …
All earning calls
Investor presentations from Dr. Lal Pathlabs …
All investor presentations